GENOVA,Inc. FY2027 Q1 Earnings Report

Quick View

Executive Summary

While Revenue continued to achieve strong growth of +64.7% year on year, the operating loss persisted, resulting in earnings that highlight ongoing challenges in the quality of revenue growth and core earnings power. Revenue was ¥30.6B (¥18.6B in the same period of the previous year, +64.7%), Operating Income was ¥-2.2B (¥-1.7B in the same period of the previous year, with the operating loss widening), and Ordinary Income was ¥-2.1B (¥-1.7B in the same period of the previous year). Net Income turned profitable at ¥2.5B (¥-1.0B in the same period of the previous year, +354.2%), but this was primarily due to a temporary boost from extraordinary income of ¥4.98B, mainly attributable to gains on the reversal of stock acquisition rights. As indicated by the operating loss, the Company’s fundamental earnings power remains in a transition phase.

Factors Affecting Earnings

【Revenue】Revenue increased to ¥30.6B, representing year-on-year growth of +64.7%. By segment, Smart Clinic posted substantial revenue growth to ¥9.8B (+43.7%), Dental Distribution added ¥8.2B through new consolidation, and the Medical Platform maintained steady growth at ¥11.4B (+7.3%). The new consolidation of the Dental Distribution business, following the acquisition of shares in Akasaka Dental Materials Co., Ltd., was one of the primary drivers of revenue growth.

【Profit and Loss】Operating Income was ¥-2.2B, with the loss widening from ¥-1.7B in the same period of the previous year. The gross profit margin declined significantly from the previous year to 50.1%, apparently due primarily to the consolidation of low-margin products in the Dental Distribution business. Meanwhile, the SG&A ratio improved significantly from the previous year to 57.4%, indicating progress in cost efficiency. Ordinary Income remained negative at ¥-2.1B; however, following the recognition of extraordinary income of ¥4.98B from gains on the reversal of stock acquisition rights, Profit Before Tax was ¥2.8B and Net Income turned profitable at ¥2.5B (+354.2%). The divergence between Net Income and Ordinary Income is temporary and attributable to extraordinary income; therefore, the results can be characterized as higher revenue but lower earnings on an operating income basis.

Segment Analysis

By segment, the Medical Platform was the largest earnings contributor, recording Operating Income of ¥2.8B (profit margin of 24.5%), although profit declined slightly by -2.4% year on year. Smart Clinic recorded Operating Income of ¥2.0B (profit margin of 20.7%), a substantial increase of +297.4% year on year, as economies of scale became evident. Dental Distribution, a newly consolidated segment, recorded an operating loss of ¥-0.7B (profit margin of -8.5%), with start-up and integration costs weighing on consolidated earnings. Other segments remained stable, recording Operating Income of ¥0.2B (+12.3%). The adjustment for company-wide common expenses increased to ¥-6.5B, exceeding the ¥4.3B in combined profit of the reported segments; this is the primary factor driving consolidated Operating Income into the red.

Key Financial Indicators

【Profitability】The Operating Income margin improved by +2.1pt to -7.3% from -9.4% in the same period of the previous year, but remained negative. The gross profit margin declined significantly to 50.1% due to the change in business mix following the consolidation of Dental Distribution, while the SG&A ratio improved to 57.4%, reflecting progress in cost efficiency. The Net Income margin was 8.2%, but was dependent on extraordinary income; on an ordinary income basis, the Company remained loss-making at -7.0%.【Cash Flow Quality】Cash and deposits stood at ¥50.8B, securing strong liquidity with a current ratio of 263.7%. Accounts receivable increased to ¥23.7B (+27.8% year on year), while accounts payable rose to ¥10.6B (+115.0%), indicating an expansion in working capital reflecting business expansion and M&A activity.【Investment Efficiency】ROE was 4.1%; considering the dependence of Net Income on extraordinary income, recurring capital efficiency can be assessed as limited. Total assets were ¥113.1B (¥102.5B in the same period of the previous year), while goodwill was ¥13.9B, equivalent to 22.7% of net assets of ¥61.5B and within a generally tolerable range.【Financial Soundness】The Equity Ratio declined to 54.4% from 67.3% in the same period of the previous year, but remained at a sound level. Long-term borrowings increased to ¥13.9B, up +124% year on year, indicating that funding for M&A and growth investments is increasingly being financed on a long-term basis.

Cash Flow Analysis

Although a standalone cash flow statement has not been disclosed, an analysis of funding trends based on changes in the balance sheet indicates that cash and deposits were ¥50.8B, a slight decrease from ¥53.2B in the same period of the previous year. The +27.8% increase in accounts receivable and the +115.0% increase in accounts payable indicate an expansion in working capital accompanying the new consolidation of Dental Distribution and business growth. If the collection cycle for trade receivables lengthens while operating losses continue, this could affect cash generation capacity. Long-term borrowings increased by +124.3%, suggesting an approach of financing growth investments and M&A with long-term funding; therefore, short-term liquidity concerns appear limited.

Quality of Earnings

The ¥2.5B Net Income profit was heavily dependent on extraordinary income of ¥4.98B, primarily gains on the reversal of stock acquisition rights, and recurring earnings power has not yet been established, as indicated by the ¥-2.2B operating loss. Non-operating income was ¥0.1B, a minor 0.4% of Revenue, whereas extraordinary income reached approximately 16.3% of Revenue, resulting in a substantial divergence between Ordinary Income of ¥-2.1B and Net Income. Amortization expenses for goodwill are compressing Operating Income, and given the increase in goodwill and intangible assets of approximately +35% year on year, monitoring future amortization expenses and impairment risk will be important in assessing earnings quality.

Earnings Forecast and Guidance

Progress in Q1 toward the full-year plan of Revenue of ¥216.0B, Operating Income of ¥15.7B, and Ordinary Income of ¥15.6B was 14.1% for Revenue, below the simple progress benchmark of 25%. Operating Income was a loss of ¥-2.2B, representing negative progress; achieving the full-year plan will therefore require substantial earnings generation and improved profitability in the second half of the fiscal year. Net Income progress was ¥2.5B/¥11.9B, or approximately 20.9%; however, this is an apparent level of progress supported by extraordinary income, and the likelihood of achieving the plan is difficult to assess without a return to profitability at the operating level. Neither the earnings forecast nor the dividend forecast was revised, with both indicated as “None.”

Shareholder Returns

The Company’s full-year dividend forecast is ¥30.00 per share. The dividend for the same period of the previous year was ¥0. The Payout Ratio against forecast EPS of ¥68.74 is approximately 43.6%. Given cash on hand of ¥50.8B and an Equity Ratio of 54.4%, the Company appears to have sufficient financial capacity to maintain dividends for the time being; however, the fact that operating results remain in the red will be subject to continued monitoring.

Risk Factors

1. Gross margin decline and earnings risk in the Dental Distribution segment: The gross profit margin declined to 50.1%, and Dental Distribution is a loss-making segment with an Operating Income margin of -8.5%. If the absorption of integration and start-up costs is prolonged, improvement in company-wide Operating Income may be delayed.

2. Working capital expansion risk: Accounts receivable and accounts payable increased sharply by +27.8% and +115.0% year on year, respectively, potentially increasing volatility in funding requirements associated with business expansion and M&A. Management of the collection cycle will be a key issue.

3. Impairment risk for goodwill and intangible assets: Goodwill increased to ¥13.9B (+35.1% year on year), while intangible fixed assets rose to ¥14.3B (+35.8%). If the integration benefits of the Dental Distribution business do not materialize as planned, there is a risk of increased amortization expenses and impairment charges.

Industry Benchmark (For Reference; Compiled by the Company)

Industry Benchmark (it_telecom)

Profitability and Returns

The Operating Income margin is significantly below the industry median, while the Net Income margin exceeds the industry median due to the boost from extraordinary income.

Growth and Capital Efficiency

The Revenue growth rate is substantially above the industry median, positioning the Company as a high-growth player within the industry, including the expansion of consolidation through M&A.

※Source: Compiled by the Company

Key Takeaways from the Financial Results

1. Although the top line achieved outstanding growth of +64.7% even within the industry, the decline in the gross profit margin and continued operating losses indicate that core earnings power remains in a transition phase from growth to monetization.

2. The return to Net Income profitability was largely attributable to the temporary impact of extraordinary income of ¥4.98B, while Ordinary Income remained negative at ¥-2.1B. Trends in operating results will be the key factor in assessing earnings sustainability.

3. The increase in goodwill to ¥13.9B and intangible fixed assets to ¥14.3B indicates progress in the M&A strategy, while the earnings improvement of the Dental Distribution segment and the degree to which company-wide common expenses are absorbed will be key points to monitor in assessing the normalization of future profitability.

Theoretical Share Price (Reference Value)

Sensitivity: ¥454–¥480 at ±1% for the cost of equity, and ¥464–¥471 at ±0.1 for ω.

Notes:

• Net assets as of the end of the quarter are used (there is a timing difference from the full-year forecast).
• As net assets include non-controlling interests, the theoretical value may be calculated somewhat higher.

(Calculation model: Residual Income Model (Ohlson-type, explicit 5-year fade) / Interest rate reference month: 2026-07 / Mechanically calculated value based solely on publicly disclosed data; this is not a forecast of the market share price or a recommendation of any specific investment action, and does not predict or guarantee future share prices.)

---

This report is an earnings analysis document automatically generated by AI through analysis of XBRL earnings release data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own discretion and responsibility, after consulting with professionals as necessary.

---End of Report---

---

AI Financial Analysis

Executive Summary

FY2027 Q1 showed strong top-line expansion and substantially improved gross profitability, but the group remained loss-making at the operating level and reported net income was predominantly supported by a non-recurring gain. Revenue increased 64.7% YoY to ¥3.06bn. Gross profit rose 23.1% YoY to ¥1.53bn, while gross margin expanded to 50.1% from 67.1% in the prior-year quarter? Wait. Based on the reported prior-period gross profit and revenue, the prior gross margin was 67.1%, so the current 50.1% represents a 1,700bp contraction. SG&A expenses increased 23.6% YoY to ¥1.75bn, materially slower than revenue growth. Consequently, the SG&A-to-sales ratio improved by approximately 19.1ppt YoY to 57.4%. Operating loss nevertheless widened to ¥0.22bn from ¥0.17bn, although the operating margin improved by about 2.1ppt to negative 7.3%. Ordinary loss was ¥0.21bn, confirming that the core business remained loss-making after finance costs. Reported net income of ¥0.25bn and EPS of ¥14.40 were driven by ¥0.50bn of extraordinary income, chiefly a ¥0.497bn gain on reversal of subscription rights to shares. Excluding this extraordinary item, pre-tax profit would have remained close to the ordinary loss, indicating that Q1 net profit does not reflect recurring earnings power. The annualized reported ROE of 16.2% is therefore not representative of sustainable returns because it incorporates the one-off extraordinary gain. The operating loss also makes the reported negative interest coverage ratio of negative 51.16x economically meaningful: interest expense is modest in absolute terms, but cannot currently be covered by EBIT. Liquidity is ample, with cash of ¥5.08bn, a current ratio of 263.7%, and cash equal to 28.22x short-term debt. Balance-sheet leverage remains manageable at 0.84x debt-to-equity and 20.3% debt-to-capital, but long-term borrowings more than doubled YoY in connection with expansion and acquisition activity. The acquisition of Akasaka Shizaisha added ¥0.38bn of goodwill and established the dental distribution business as a new revenue contributor, but this also raises integration and future goodwill-value-retention considerations. Q1 revenue represents 14.1% of the ¥21.60bn full-year sales forecast, below the standard 25% first-quarter pace, while the operating result is negative against a full-year ¥1.57bn operating-profit target. Delivering guidance will require a pronounced improvement in profitability over the remaining quarters, alongside conversion of the acquired dental distribution operation toward profitability.

Profitability Analysis

The reported annualized DuPont ROE is 16.2%, comprising an 8.2% net profit margin, 1.081x asset turnover, and 1.84x financial leverage. The net margin is the principal driver of the reported return, but it was inflated by the ¥0.50bn extraordinary gain; it should not be read as evidence of recurring operating profitability. Financial leverage is moderate rather than aggressive, with debt-to-equity at 0.84x, so leverage is not the main explanation for the high reported ROE. The underlying earnings issue is negative EBIT of ¥0.22bn and an EBIT margin of negative 7.3%, despite 64.7% revenue growth. Gross margin declined by approximately 1,700bp YoY to 50.1%, reflecting a less favorable revenue mix and/or acquisition-related cost structure relative to the exceptionally high prior-year comparison. SG&A rose 23.6%, well below sales growth, producing meaningful operating leverage in the SG&A ratio; however, the absolute SG&A base of ¥1.75bn still exceeded gross profit of ¥1.53bn. Segment contribution highlights the distinction between businesses and corporate cost absorption. Medical Platform generated revenue of ¥1.14bn and segment profit of ¥0.28bn, versus revenue of ¥1.06bn and profit of ¥0.29bn a year earlier; its margin declined from 26.9% to 24.5%. Smart Clinic generated revenue of ¥0.98bn and segment profit of ¥0.20bn, compared with ¥0.68bn and ¥0.05bn, respectively, lifting its segment margin from 7.5% to 20.7%. Dental Distribution contributed ¥0.82bn of revenue but incurred a segment loss of ¥0.07bn, making post-acquisition margin normalization important. Other businesses generated ¥0.12bn of revenue and ¥0.02bn of segment profit. Aggregate segment profit increased to ¥0.43bn from ¥0.35bn, but unallocated corporate costs and goodwill amortization widened to ¥0.65bn from ¥0.53bn, more than offsetting business-level profit. The ¥19m goodwill amortization included in the adjustment is a recurring JGAAP acquisition-accounting expense and depresses operating profit relative to IFRS comparables, although the much larger corporate-cost burden remains the decisive reason for the consolidated operating loss. The quality alert for annualized ROIC of negative 29.6% is consistent with negative operating earnings and signals that the enlarged invested-capital base is not yet earning an adequate operating return.

Growth Assessment

Revenue growth was broad-based, with Medical Platform up 7.3% YoY, Smart Clinic up 43.7%, and the newly consolidated Dental Distribution operation contributing ¥0.82bn. Smart Clinic was the strongest contributor to incremental segment profit, with profit increasing by ¥0.15bn YoY. Medical Platform remains the core business by segment-profit contribution at ¥0.28bn, but its profit declined slightly despite revenue growth, indicating some margin pressure. Dental Distribution expands the group’s addressable medical and dental ecosystem but was loss-making in its first consolidated quarter. The acquisition added ¥0.38bn of goodwill, and realizing cross-selling, procurement, and operating synergies will be central to validating the transaction economics. Full-year guidance assumes 86.8% sales growth to ¥21.60bn and operating profit of ¥1.57bn, compared with a Q1 operating loss of ¥0.22bn. Q1 sales progress is 14.1%, 10.9ppt below the standard 25% pace for a first quarter. Operating-profit progress is negative versus the full-year target, implying that the group must generate approximately ¥1.80bn of operating profit over Q2-Q4. The scale of the required sequential improvement makes execution on sales growth, gross-margin recovery, and corporate-cost absorption the main determinants of forecast credibility. No forecast revision has been announced.

Financial Health

Liquidity is strong. Current assets of ¥8.14bn exceeded current liabilities of ¥3.09bn, producing working capital of ¥5.06bn and a current ratio and quick ratio of 263.7%. Cash and deposits of ¥5.08bn account for 44.9% of total assets and provide substantial near-term funding flexibility. Short-term loans were only ¥0.18bn, while cash covered short-term debt by 28.22x; accordingly, there is no evident short-term maturity mismatch. Total interest-bearing debt was ¥1.57bn, comprising ¥0.18bn of short-term loans and ¥1.39bn of long-term loans. Debt-to-equity of 0.84x is below the 2.0x aggressive-leverage threshold, and debt-to-capital of 20.3% is conservative. Long-term loans increased ¥0.77bn, or 124.3% YoY, and should be monitored as the group finances expansion and M&A. Accounts payable increased ¥0.57bn, or 115.0% YoY, broadly alongside the expansion of the business base and the addition of dental distribution operations. Accounts receivable rose ¥0.52bn, or 27.8% YoY, to ¥2.37bn. The quality alert of 71 days sales outstanding, above the 60-day benchmark, warrants attention because further collection-period elongation would tie up cash and could weaken conversion of rapid revenue growth into liquidity. Goodwill and intangible assets total ¥2.82bn, equal to 24.9% of assets. Goodwill equals 22.7% of equity and 12.3% of assets, remaining below the stated elevated-risk thresholds, but its increase following the acquisition increases dependence on successful integration and acquired-business performance. Deferred tax assets of ¥0.59bn are also a meaningful 5.3% of assets and depend on the generation of future taxable income for realization.

Notable B/S Changes

Long-term loans: +¥0.77bn (+124.3%) to ¥1.39bn — increased funding commitments following expansion and acquisition activity; leverage remains manageable but debt-service capacity depends on restoring positive EBIT. Accounts payable: +¥0.57bn (+115.0%) to ¥1.06bn — reflects a larger operating base and likely the addition of dental distribution purchasing activity; monitor supplier-financing dependence. Intangible assets: +¥0.38bn (+35.8%) to ¥1.43bn — acquisition-related intangible-asset growth increases the importance of post-deal earnings realization. Goodwill: +¥0.36bn (+35.1%) to ¥1.39bn — principally associated with the Akasaka Shizaisha acquisition; goodwill is 22.7% of equity and requires successful integration to avoid impairment risk. Accounts receivable: +¥0.52bn (+27.8%) to ¥2.37bn — rapid sales growth has increased working-capital requirements; the 71-day DSO alert makes collection efficiency a key monitoring item.

Cash Flow Quality

The Q1 profit figure has weak underlying earnings quality because net income of ¥0.25bn was generated despite an operating loss of ¥0.22bn and ordinary loss of ¥0.21bn. The principal reconciling item was ¥0.50bn of extraordinary income, mainly the ¥0.497bn gain on reversal of subscription rights to shares. This item is non-recurring and does not provide operating cash-generating capacity. The widening receivables balance and 71-day DSO are the principal working-capital items to monitor as sales scale. Accounts payable also increased substantially, which partly supports near-term working capital but should be assessed against the sustainability of supplier terms and acquired-business purchasing volumes. The acquisition-related increase in goodwill of ¥0.38bn demonstrates active capital deployment, increasing the importance of future cash conversion from the Dental Distribution business. Cash balances are substantial at ¥5.08bn, providing a buffer for operating losses, debt service, integration spending, and shareholder distributions. The current period data supports analysis of earnings composition and balance-sheet liquidity, with the reported extraordinary gain being the main factor affecting profit quality.

Dividend Sustainability

The full-year dividend forecast is ¥30.00 per share. Against forecast EPS of ¥68.74, the implied dividend payout ratio is approximately 43.6%, which is within the stated sub-60% sustainability benchmark. Using 17.34 million average shares, the indicated annual cash dividend would be approximately ¥0.52bn. This is below forecast attributable profit of ¥1.19bn, leaving an implied earnings retention buffer of roughly ¥0.67bn. The stated dividend is therefore supportable on the company’s full-year earnings forecast and substantial cash balance of ¥5.08bn. However, Q1 recurring profitability was negative at the operating and ordinary-income levels, so delivery of the planned payout relies on the expected material profit recovery through the remaining three quarters. Maintaining the dividend policy will depend on achieving guidance while integrating the dental acquisition without further deterioration in operating margins or collection efficiency.

Risk Assessment

Business risks include High priority — Guidance-execution risk: Q1 revenue reached only 14.1% of the full-year sales plan and operating income was negative against a ¥1.57bn full-year target, requiring a sharp Q2-Q4 profitability recovery., High priority — Corporate-cost absorption risk: unallocated costs, including ¥19m of goodwill amortization, were ¥0.65bn and exceeded total segment profit of ¥0.43bn; insufficient scale or cost discipline would prolong consolidated operating losses., High priority — Dental Distribution integration risk: the acquired business contributed ¥0.82bn of revenue but a ¥0.07bn segment loss, while adding ¥0.38bn of goodwill., Medium priority — Margin-mix risk: consolidated gross margin contracted about 1,700bp YoY to 50.1%, and Medical Platform’s segment margin declined to 24.5% from 26.9%., Medium priority — Medical and dental digital-services execution risk: growth depends on maintaining customer acquisition, adoption, and service differentiation in healthcare-related platform, clinic-support, and distribution markets..

Financial risks include High priority — Debt-service risk: interest coverage was negative 51.16x because EBIT was negative. Interest expense is only ¥0.04bn, but ongoing operating losses would make debt servicing dependent on cash reserves rather than operating earnings., Medium priority — Borrowing increase: long-term loans rose 124.3% YoY to ¥1.39bn. Leverage is currently manageable, but continued debt-funded acquisitions would increase financial risk., Medium priority — Receivables collection risk: DSO of 71 days exceeds the 60-day alert threshold and receivables increased 27.8% YoY to ¥2.37bn., Medium priority — Goodwill impairment risk: goodwill increased 35.1% YoY to ¥1.39bn. Goodwill-to-equity remains moderate at 22.7%, but a failure to turn Dental Distribution profitable could pressure carrying values., Low priority — Liquidity risk: current ratio of 263.7%, quick ratio of 263.7%, and ¥5.08bn cash provide strong near-term liquidity protection..

Key concerns include The reported ¥0.25bn net profit was primarily attributable to a ¥0.50bn extraordinary gain rather than recurring operations., Annualized ROIC of negative 29.6% indicates the company is not yet producing an adequate operating return on its invested capital., The negative 7.3% EBIT margin and negative interest coverage directly address the low-operating-efficiency and high-interest-burden quality alerts., The full-year earnings outlook requires a substantial acceleration in both margin and operating-profit generation after Q1..

Investment Implications

Key takeaways include Revenue momentum is strong, supported by Smart Clinic growth and the newly consolidated Dental Distribution operation., Business-segment profitability improved in aggregate, especially in Smart Clinic, but consolidated profitability remains constrained by corporate costs and acquisition-related amortization., Net income, annualized ROE, and Q1 EPS overstate recurring performance because of the ¥0.497bn gain on reversal of subscription rights to shares., Liquidity and balance-sheet leverage are currently sound, providing capacity to absorb integration costs and temporary operating losses., The central operating test is whether Q2-Q4 can convert scale into sufficient gross profit and cost absorption to meet the ¥1.57bn full-year operating-income target..

Metrics to watch include Quarterly operating margin and gross margin, particularly recovery from Q1's negative 7.3% EBIT margin and 50.1% gross margin, Unallocated corporate costs relative to total segment profit, Dental Distribution revenue, segment margin, synergy realization, and goodwill carrying value, Smart Clinic segment-profit durability after its Q1 margin expansion to 20.7%, Receivables growth and DSO relative to the current 71 days, Long-term debt growth, interest coverage, and cash balances, Progress toward the ¥21.60bn revenue, ¥1.57bn operating-income, and ¥1.19bn net-income forecasts.

Regarding relative positioning, GENOVA combines strong reported growth and a liquid, moderately leveraged balance sheet with currently weak consolidated operating efficiency. Its JGAAP goodwill amortization modestly reduces operating profit relative to IFRS peers, but the more material differentiator is the large corporate-cost base relative to segment earnings. Near-term relative performance will depend on whether acquisition-led scale and Smart Clinic momentum can create sustainable operating leverage rather than merely revenue expansion.